PROG (NYSE:PRG) Q3 2025 Earnings Call October 22, 2025 08:30 AM ET Speaker0Day, and thank you for standing by. Welcome to the Brock Holdings Third Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please note that today's conference is being recorded.I will now hand the conference over to your speaker host, John Bubb, Vice President of Investor Relations. Please go ahead.Speaker1Thank you ...

Weatherford International (NasdaqGS:WFRD) Q3 2025 Earnings Call October 22, 2025 08:30 AM ET Speaker0Ladies and gentlemen, thank you for standing by. Welcome to the Weatherford International Third Quarter twenty twenty five Results. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. As a reminder, today's event is being recorded.I would now like to turn the conference over to Luke Lemoyne, Senior Vice President of Corporate Development. P ...

Chubb (NYSE:CB) Q3 2025 Earnings Call October 22, 2025 08:30 AM ET Speaker1Thank you for standing by. My name is Eric and I will be your conference operator today. At this time I would like to welcome everyone to the Chubb Limited third quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press STAR followed by the number one on you ...

Wabtec (NYSE:WAB) Q3 2025 Earnings Call October 22, 2025 08:30 AM ET Speaker2Today, and welcome to the Wabtec Third Quarter 2025 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one, on a touch-tone telephone. To withdraw your question, please press star, the ...

Financial Data and Key Metrics Changes - Total revenues grew by 1.6% year over year, adjusted EBITDA increased by 2.4%, and adjusted EBITDA margins expanded by 30 basis points [12] - Adjusted EPS was $0.54, consistent with the prior year, while free cash flow was $4.9 billion compared to $4.6 billion a year ago [12][26] - Capital investment decreased to $5.3 billion, down $200 million year over year [13] Business Line Data and Key Metrics Changes - Mobility service revenue grew by 2.3% year over year, contributing to EBITDA growth of 2.2% [14] - Consumer Wireline revenues increased by 4.1%, driven by a 16.8% growth in fiber revenue, with Consumer Wireline EBITDA growing over 15% [19] - Business Wireline revenues declined by 7.8% year over year, while EBITDA decreased by about 13% [22] Market Data and Key Metrics Changes - Over 400,000 postpaid phone net adds were recorded, slightly ahead of the previous year's performance [3] - AT&T Fiber subscribers surpassed 10 million, with the company achieving its highest total broadband net adds in over eight years [5][21] - The convergence rate of fiber customers who also subscribe to mobility services reached 41.5%, up 180 basis points from a year ago [21] Company Strategy and Development Direction - The company aims to become the best advanced communications provider in America and lead the industry in retail connectivity service revenue by the end of the decade [7] - Planned acquisitions of spectrum licenses from EchoStar and fiber assets from Lumen are expected to enhance the advanced connectivity portfolio [7][9] - The company is focused on transitioning away from legacy infrastructure and investing in AI-ready connectivity [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year financial guidance, with expectations for service revenue growth in the low single-digit range and adjusted EBITDA growth of 3% or better [26] - The competitive environment remains challenging, but the company believes its focus on converged customer relationships will drive profitability and reduce churn [61][65] - Management is optimistic about the impact of upcoming acquisitions on organic growth and profitability [28][90] Other Important Information - The company returned $3.5 billion to shareholders, including nearly $1.5 billion in stock repurchases [23] - The company ended the quarter with over $20 billion in cash, positioning it well for capital returns and pending acquisitions [24] - The company expects to achieve full-year free cash flow in the low to mid-$16 billion range [26] Q&A Session Summary Question: Concerns about fiber expansion and competition - Management expressed confidence in their ability to build effectively and penetrate markets, stating that they have a scalable build engine and can manage capital allocation strategically [31][35] Question: Fixed Wireless Access (FWA) market segmentation - Management highlighted the importance of targeted marketing and operational support to ensure effective segmentation between fiber and fixed wireless offerings [43][46] Question: Impact of competitive activity on wireless margins - Management believes they are well-positioned for a competitive market and will continue to focus on converged customers to drive profitability [60][62] Question: Confidence in Lumen and EchoStar acquisitions - Management reiterated confidence in the strategic value of the Lumen and EchoStar assets, expecting them to enhance organic growth and profitability [81][84]

Weatherford International (NasdaqGS:WFRD) Q3 2025 Earnings Call October 22, 2025 08:30 AM ET Speaker0Ladies and gentlemen, thank you for standing by. Welcome to the Weatherford International Third Quarter twenty twenty five Results. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. As a reminder, today's event is being recorded.I would now like to turn the conference over to Luke Lemoyne, Senior Vice President of Corporate Development. P ...

Thermo Fisher Scientific (NYSE:TMO) Q3 2025 Earnings Call October 22, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 third quarter conference call. My name is Claire, and I will be coordinating your call today. During the presentation, you can register a question by pressing * followed by 1 on your telephone keypad. If you change your mind, please press * followed by 2 on your telephone keypad. I would like to introduce our moderator for the cal ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was reported at $464.3 million, an 8.5% increase year-over-year [7] - Net income and diluted earnings per share were reported at $43.59 per share, including a $0.39 benefit related to the ERC [10] - Cash flow from operations was reported at $71.3 million, adjusted to $87.1 million after accounting for a decrease in payroll accrual [10] Business Line Data and Key Metrics Changes - Environmental services revenue was reported at $211.8 million, while dietary services revenue was $252.5 million [7] - Segment margins for environmental and dietary services were reported at 10.7% and 5.1%, respectively [9] Market Data and Key Metrics Changes - The company noted a strong labor market, with skilled nursing job gains significantly outpacing 2024 levels, although still about 30,000 jobs short of pre-pandemic levels [25] - The company continues to see a positive trend in cash collection and a strong balance sheet, with cash and marketable securities of $207.5 million [11] Company Strategy and Development Direction - The top three strategic priorities for Q4 include driving growth through management development, managing costs through operational execution, and optimizing cash flow [6] - The company is focusing on organic growth, strategic acquisitions, and opportunistic share repurchases, with a $50 million share repurchase plan valid through June 2026 [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term care market, citing a multi-decade demographic tailwind and stable reimbursement environment [5] - The company is confident in its ability to capitalize on growth opportunities while delivering sustainable, profitable results [6] Other Important Information - The company repurchased $27.3 million of common stock in Q3, bringing year-to-date buybacks to $42 million [12] - The company continues to evaluate M&A opportunities, particularly in the education sector, which is a top target for acquisitions [19] Q&A Session Summary Question: Pipeline of new client wins and future growth - Management indicated that the majority of Q3 growth was driven by new business wins and high client retention rates, with an estimated revenue range of $460 to $470 million for Q4 [15][16] Question: Labor market and hiring capabilities - Management noted that the labor market is strong, with record application levels and sufficient staffing to support growth, despite some ongoing challenges in specific markets [25][26] Question: Outsourcing trends in Environmental and Dietary Services - Management observed an increasing acceptance of outsourcing in both environmental and dietary services, with significant growth potential in the market [32][35] Question: Update on Genesis Healthcare and facility transitions - Management confirmed that services to Genesis Healthcare facilities continue without disruption, and the company is monitoring the bankruptcy process closely [36][37]

CME Group (NasdaqGS:CME) Q3 2025 Earnings Call October 22, 2025 08:30 AM ET Speaker0Welcome to the CME Group Third Quarter twenty twenty five Earnings Call. I would now like to turn the call over to Adam Minnick. Please go ahead.Speaker1Good morning, and I hope you're all doing well today. We released our executive commentary earlier this morning, which provides extensive details on the third quarter twenty twenty five, which we will be discussing on this call. I'll start with the Safe Harbor language and t ...

Financial Data and Key Metrics Changes - Total company operational sales grew 19% in Q3 2025, while organic sales increased by 15%, exceeding the guidance range of 12% to 14% [6][22] - Adjusted EPS for Q3 2025 was $0.75, reflecting a 19% growth and surpassing the guidance range of $0.70 to $0.72 [6][22] - Adjusted operating margin for Q3 was 28%, with an adjusted gross margin of 71%, showing a 60 basis point improvement year-over-year [23][6] Business Line Data and Key Metrics Changes - Urology sales grew 27% operationally and 5% organically, driven by international business and Global Stone Management [9] - Endoscopy experienced a 9% growth, with double-digit growth in key products [10] - Neuromodulation sales increased by 9%, supported by strong performance in the brain franchise [10] - Peripheral interventions sales grew 16% operationally and 6% organically, with low single-digit growth in arterial due to pricing pressures in China [11] Market Data and Key Metrics Changes - U.S. operational sales grew 27%, with strong performance across cardiovascular businesses, endoscopy, and neuromodulation [7] - Europe, Middle East, and Africa (EMEA) saw a 2% decline operationally due to specific headwinds, while Asia-Pacific grew 17% operationally [7][8] - China experienced mid-teens growth, driven by strong performance in electrophysiology and the recent approval of the Watchman Flex Pro device [8][9] Company Strategy and Development Direction - The company is focused on sustaining above-market growth, with a full-year 2025 organic growth guidance of approximately 15.5% [6][25] - The acquisition of Nalu Medical is expected to expand the company's portfolio into a new pain adjacency, complementing its existing strengths [11][81] - The company aims to achieve 10% plus average organic revenue growth from 2026 to 2028, along with annual adjusted operating margin expansion [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth despite challenges, with a focus on innovation and clinical evidence generation [20][39] - The company does not anticipate procedural pull-forwards due to external pressures, maintaining consistent procedural demand [38] - Management remains optimistic about the growth potential in the electrophysiology and Watchman markets, projecting a 20% CAGR over the long-range plan [33][48] Other Important Information - The company faced a $30 million backorder due to an ERP system upgrade, impacting various business lines but expected to improve in Q4 [7][75] - The company maintains a strong cash position with $1.275 billion on hand and a gross debt leverage ratio of 2.0 times [24] Q&A Session Summary Question: Is Watchman a key growth driver? - Management confirmed that Watchman is a significant growth driver, with expectations of continued market expansion and strong adoption rates [32][34] Question: What is the outlook for the China market? - Management indicated strong growth in China, with expectations for continued double-digit growth despite pricing pressures [39][40] Question: How will the new product cycle impact CRM growth? - Management expressed confidence in the upcoming Denali platform and Empower leadless pacemaker, anticipating improved growth in the CRM segment [85][86] Question: What are the drivers for growth outside EP and Watchman? - Management highlighted strong performance in neuromodulation, endoscopy, and the potential of the Nalu acquisition to enhance growth in the pain management segment [60][61]